[New indications for erythropoietin in clinical practice].
The utilization of rHuEp changed definitively the treatment and the natural history of anemia in patients with chronic renal insufficiency (CRI), and now is modifying the treatment of anemia of other non-renal patients as anemia of premature, anemia in onco-hematological illnesses, anemia in human immunodeficiency virus (HIV) infection, and for reduction of allogenic blood transfusions in surgery. We analyze briefly the clinical indications of rHuEpo and the possible complications secondary to its use.
Fernández Lago
C
C
Servicio de Hematología y Hemoterapia, Complexo Hospitalario Universitario Juan Canalejo, La Coruña, Departamento de Medicina, Universidad de Santiago de Compostela, La Coruna, Spain. CFerLag@canalejo.org
Batlle Fonrodona
J
J
D000740:Anemia / Q000188:drug therapy* / Q000209:etiology; D004921:Erythropoietin / Q000627:therapeutic use*; D006801:Humans; D007676:Kidney Failure, Chronic / Q000150:complications
D004921:Erythropoietin